Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kyowa Hakko Kirin
Biotech
Mei, with Bayer and Gilead in its sights, posts pivotal data
The pivotal trial linked zandelisib to a 70% response rate but leaves scope to question whether the drug can crack a competitive space.
Nick Paul Taylor
Nov 30, 2021 9:10am
Amgen reveals midphase eczema data behind its $400M bet
Oct 4, 2021 7:10am
Kyowa Kirin licenses AM-Pharma phase 3 asset for up to $289M
Sep 8, 2021 9:28am
Amgen reunites with Kyowa Kirin in $400M dermatitis deal
Jun 1, 2021 4:00am
MEI Pharma nabs $100M upfront in new Kyowa Kirin deal
Apr 14, 2020 7:15am
GSK files for Japanese approval of oral anemia drug
Aug 21, 2019 8:54am
